Cargando…
Case Report: A Presentation of Early-Onset Immune-Mediated Bullous Pemphigoid in a Patient with Urothelial Cancer
Cutaneous immune-related adverse events (cirAEs) are the most common side effects of immune checkpoint inhibitor (ICI) therapy (30–50% for all grades). The vast majority of them are low or mild and can be treated without ICI interruption. Autoimmune blistering disorders, such as immune-mediated bull...
Autores principales: | Sabaté Ortega, Josep, Fort Culillas, Roser, Escoda Garcia, Marina, Vásquez-Dongo, Carmen Amalia, Sala González, Núria |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10529691/ https://www.ncbi.nlm.nih.gov/pubmed/37754481 http://dx.doi.org/10.3390/curroncol30090566 |
Ejemplares similares
-
Delayed Onset of Bullous Pemphigoid Secondary to Nivolumab
por: Olsen, Eric, et al.
Publicado: (2023) -
Bullous pemphigoid
por: Miyamoto, Denise, et al.
Publicado: (2019) -
Bullous Pemphigoid and Other Pemphigoid Dermatoses
por: Pratasava, Valeryia, et al.
Publicado: (2021) -
New‐onset bullous pemphigoid and flare of pre‐existing bullous pemphigoid after the third dose of the COVID‐19 vaccine
por: Bardazzi, Federico, et al.
Publicado: (2022) -
Bullous Pemphigoid Presenting with Esophagitis Dissecans Superficialis
por: Inoue, Kunimitsu, et al.
Publicado: (2017)